タチバナ　ヒデカズ   Hidekazu Tachibana   橘　秀和    所属   医学部 医学科（東京女子医科大学病院）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
掲載誌名	正式名：International journal of urology : official journal of the Japanese Urological Association 略　 称：Int J Urol ISSNコード：09198172/14422042
掲載区分	国外
巻・号・頁	28(1),pp.99-106
著者・共著者	ISHIHARA Hiroki†, FUKUDA Hironori, TAKAGI Toshio, KONDO Tsunenori*, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, IIZUKA Junpei, KOBAYASHI Hirohito, ISHIDA Hideki, TANABE Kazunari
発行年月	2021/01
概要	OBJECTIVES:To compare the efficacy of nivolumab with that of molecular-targeted therapy as a second-line therapy for metastatic renal cell carcinoma using real-world data.METHODS:We retrospectively evaluated patients who received nivolumab or molecular-targeted therapy after the failure of first-line molecular-targeted therapy between January 2008 and December 2019 at two Japanese institutions. Progression-free survival and overall survival after the initiation of second-line therapy were calculated using the Kaplan-Meier method and compared using the log-rank test. Objective response rate was assessed based on the Response Evaluation Criteria in Solid Tumors version 1.1.RESULTS:Among 159 patients, 43 (27%) and 116 (73%) patients received nivolumab and molecular-targeted therapy as second-line therapy, respectively. During follow up (median 11.1 months), 129 (81%) and 98 (62%) patients had disease progression and died, respectively. Progression-free survival was comparable between the two treatments (median 5.06 vs 5.95 months, P = 0.881), whereas overall survival was significantly longer with nivolumab than with molecular-targeted therapy (not reached vs 13.0 months, P = 0.0008). Multivariate analysis further showed that nivolumab therapy was an independent favorable factor for overall survival (hazard ratio 0.33, P = 0.0007). In 151 patients with eligible radiographic data, the objective response rate was significantly higher in nivolumab than in molecular-targeted therapy (n = 14/41 [34%] vs n = 20/110 [18%], P = 0.0485).CONCLUSIONS:Real-world data analysis suggests superior efficacy of nivolumab over molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma.
DOI	10.1111/iju.14412
PMID	33159426